成都先导拟增资参股公司先衍生物，专注小核酸新药研发

Group 1 - The core point of the article is that Chengdu XianDao plans to invest 24 million yuan in a stake in XianYan Biological, with a pre-investment valuation of 450 million yuan. XianYan focuses on the development of small nucleic acid new drugs, with its hypertension drug LDR2402 entering Phase II clinical trials and the obesity drug LDR2515 recently receiving implied permission for clinical trials. The investment round is led by Daoyuan Guosheng, with a total financing amount not exceeding 150 million yuan, and Chengdu XianDao's shareholding will be adjusted based on the financing results [1] Group 2 - In the recent stock performance, Chengdu XianDao's stock price fluctuated between 29.84 yuan and 30.26 yuan over the past week, with a range of 13.48%. The capital flow indicates a divergence in main funds, with a net inflow of 45.28 million yuan on February 10, followed by a net outflow of 12.56 million yuan on February 11. As of February 12, the turnover rate was 2.04%, with a single-day increase of 1.44% [2]